Effectiveness and safety of modified shorter treatment regimens for MDR/RR-TB in Latvia

Līga Kukša (Coresponding Author), Olena Kulikova, Nityanand Jain

Research output: Contribution to conferencePosterpeer-review

1 Downloads (Pure)


In Latvia, since 2018, completely oral regimen has been used in the treatment of RR/MDR TB. This approach is fully based on the latest WHO guidelines issued in March 2019. Experience and treatment results show rapid and stable sputum conversion and cure of patients, even with HIV coinfection. As current evidence showed high effectiveness of shorter treatment regimens in 2020 Latvia joined WHO Euro initiative on mSTR.

Aim of this study is to evaluate preliminary effectiveness and safety of mSTR. All RR/MDR-TB patients detected between February 2020 – February 2021 were screened for enrollment to the study.Enrolled patients were treated with bedaquiline, levofloxacin, linezolid, clofazimine and cycloserine or delamanid for 39 weeks. We conducted descriptive statistics to describe sample characteristics and study outcomes.

Preliminary data show favorable treatment outcomes up 70%. One third of patients experienced significant toxicity mainly after third month of treatment, but only one fifth AE resolved with sequelea. Close clinical monitoring and early detection of adverse effects is important component of the treatment program.


  • tuberculosis
  • mSTR
  • treatment

Field of Science*

  • 3.3 Health sciences

Publication Type*

  • 3.4. Other publications in conference proceedings (including local)


Dive into the research topics of 'Effectiveness and safety of modified shorter treatment regimens for MDR/RR-TB in Latvia'. Together they form a unique fingerprint.

Cite this